Dopamine antagonists function by binding to dopamine receptors, primarily the D2 subtype, preventing dopamine from exerting its effects. This inhibition can be beneficial in conditions where there is an overactivity of dopamine pathways. For instance, in schizophrenia, excessive dopamine activity is linked to hallucinations and delusions. By reducing dopamine signaling, these symptoms can be managed more effectively.
